ICU Earnings

ICU reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 183.00K against an estimate of 250.00K, resulting in a -26.8% surprise. The EPS was -0.13, surpassing the expected -0.15 by 13.33%. The stock experienced a -17.39% price change on the earnings day and a -32.36% change over the next five days, reflecting market reactions to the results.

Following ICU's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by -17.39% on the day of the release. Over the subsequent five days, it saw a -32.36% change. Historically, ICU's stock price tends to shift by an average of 8.1% in the 10 days leading up to earnings and -16.15% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ICU's annual revenue to reach 245.00K, while the EPS is projected at -0.11. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ICU's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ICU's stock price typically moves by 8.1% in the 10 days before its earnings and -16.15% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.11 and revenue of 245.00K.

The earnings call highlights a fourfold revenue increase and a significant reduction in net loss, suggesting improved financial performance. The company is expanding its market presence with QUELIMMUNE and has a substantial market opportunity in adult AKI. Despite some regulatory and competitive risks, the management's optimistic outlook on faster approvals and pipeline growth is encouraging. The Q&A session revealed active engagement in clinical trials and expansion in pediatric sites, supporting a positive sentiment. Overall, the financial improvements and strategic positioning point to a potential 2% to 8% stock price increase.